Development of Selective Covalent Janus Kinase 3 Inhibitors

Journal of Medicinal Chemistry

Volumn 58, Issue 16, 2015, Pages 6589-6606

  Tan, Li ^a,b   Akahane, Koshi ^b   McNally, Randall ^a,b   Reyskens, Kathleen M S E ^c   Ficarro, Scott B ^a,b   Liu, Suhu ^b   Herter Sprie, Grit S ^b   Koyama, Shohei ^b   Pattison, Michael J ^c   Labella, Katherine ^b   Johannessen, Liv ^a,b   Akbay, Esra A ^b   Wong, Kwok Kin ^b   Frank, David A ^b   Marto, Jarrod A ^a,b   Look, Thomas A ^b   Arthur, J Simon C ^c   Eck, Michael J ^a,b   Gray, Nathanael S ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 DICHLORO N (3 NITROBENZYL)PYRIMIDIN 4 AMINE; 5 CHLORO N 2 [2 METHOXY 4 (4 METHYLPIPERAZIN 1 YL)PHENYL] N 4 (3 NITROBENZYL)PYRIMIDINE 2,4 DIAMINE; CYSTEINE; JANUS KINASE 3 INHIBITOR; N [3 (((5 CHLORO 2 ((2 METHOXY 4 (4 METHYLPIPERAZIN 1 YL)PHENYL)AMINO)PYRIMIDIN 4 YL)AMINO)METHYL)PHENYL]ACRYLAMIDE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; JANUS KINASE 3; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL VIABILITY ASSAY; COMPETITIVE BINDING ASSAY; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; ENZYMATIC ASSAY; IC50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TRANSFORMED CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CELL SURVIVAL; CHEMICAL STRUCTURE; DRUG SCREENING; HUMAN; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; JANUS KINASE 3; MALE; MICE; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940515109     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00710     Document Type: Article

References (80)

1. Darnell, J. E., Jr. ; Kerr, I. M.; Stark, G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 1994, 264 (5164) 1415-1421 10.1126/science.8197455
2. Stark, G. R.; Darnell, J. E., Jr. The JAK-STAT pathway at twenty Immunity 2012, 36 (4) 503-514 10.1016/j.immuni.2012.03.013
3. O'Shea, J. J.; Gadina, M.; Schreiber, R. D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway Cell 2002, 109 (2) S121-S131 10.1016/S0092-8674(02)00701-8
4. Ghoreschi, K.; Laurence, A.; O'Shea, J. J. Janus kinases in immune cell signaling Immunol. Rev. 2009, 228 (1) 273-287 10.1111/j.1600-065X.2008.00754.x
5. Johnston, J. A.; Bacon, C. M.; Riedy, M. C.; O'Shea, J. J. Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency J. Leukocyte Biol. 1996, 60 (4) 441-452
6. Boudny, V.; Kovarik, J. JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription Neoplasma 2002, 49 (6) 349-355
7. Baker, S. J.; Rane, S. G.; Reddy, E. P. Hematopoietic cytokine receptor signaling Oncogene 2007, 26 (47) 6724-6737 10.1038/sj.onc.1210757
8. Villarino, A. V.; Kanno, Y.; Ferdinand, J. R.; O'Shea, J. J. Mechanisms of Jak/STAT signaling in immunity and disease J. Immunol. 2015, 194 (1) 21-27 10.4049/jimmunol.1401867
9. O'Shea, J. J.; Schwartz, D. M.; Villarino, A. V.; Gadina, M.; McInnes, I. B.; Laurence, A. The JAK-STAT pathway: impact on human disease and therapeutic intervention Annu. Rev. Med. 2015, 66, 311-328 10.1146/annurev-med-051113-024537
10. Quintas-Cardama, A.; Vaddi, K.; Liu, P.; Manshouri, T.; Li, J.; Scherle, P. A.; Caulder, E.; Wen, X.; Li, Y.; Waeltz, P.; Rupar, M.; Burn, T.; Lo, Y.; Kelley, J.; Covington, M.; Shepard, S.; Rodgers, J. D.; Haley, P.; Kantarjian, H.; Fridman, J. S.; Verstovsek, S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms Blood 2010, 115 (15) 3109-3117 10.1182/blood-2009-04-214957
11. Flanagan, M. E.; Blumenkopf, T. A.; Brissette, W. H.; Brown, M. F.; Casavant, J. M.; Shang-Poa, C.; Doty, J. L.; Elliott, E. A.; Fisher, M. B.; Hines, M.; Kent, C.; Kudlacz, E. M.; Lillie, B. M.; Magnuson, K. S.; McCurdy, S. P.; Munchhof, M. J.; Perry, B. D.; Sawyer, P. S.; Strelevitz, T. J.; Subramanyam, C.; Sun, J.; Whipple, D. A.; Changelian, P. S. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection J. Med. Chem. 2010, 53 (24) 8468-8484 10.1021/jm1004286
12. Tam, C. S.; Verstovsek, S. Investigational Janus kinase inhibitors Expert Opin. Invest. Drugs 2013, 22 (6) 687-699 10.1517/13543784.2013.774373
13. Clark, J. D.; Flanagan, M. E.; Telliez, J. B. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases J. Med. Chem. 2014, 57 (12) 5023-5038 10.1021/jm401490p
14. Rosenthal, A.; Mesa, R. A. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms Expert Opin. Pharmacother. 2014, 15 (9) 1265-1276 10.1517/14656566.2014.913024
15. Mascarenhas, J. O.; Cross, N. C.; Mesa, R. A. The future of JAK inhibition in myelofibrosis and beyond Blood Rev. 2014, 28 (5) 189-196 10.1016/j.blre.2014.06.002
16. Geyer, H. L.; Mesa, R. A. Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood 2014, 124 (24) 3529-3537 10.1182/blood-2014-05-577635
17. Menet, C. J.; Rompaey, L. V.; Geney, R. Advances in the discovery of selective JAK inhibitors Progress in medicinal chemistry 2013, 52, 153-223 10.1016/B978-0-444-62652-3.00004-1
18. Dymock, B. W.; Yang, E. G.; Chu-Farseeva, Y.; Yao, L. Selective JAK inhibitors Future Med. Chem. 2014, 6 (12) 1439-1471 10.4155/fmc.14.92
19. Norman, P. Selective JAK inhibitors in development for rheumatoid arthritis Expert Opin. Invest. Drugs 2014, 23 (8) 1067-1077 10.1517/13543784.2014.918604
20. Rochman, Y.; Spolski, R.; Leonard, W. J. New insights into the regulation of T cells by gamma(c) family cytokines Nat. Rev. Immunol. 2009, 9 (7) 480-490 10.1038/nri2580
21. Wang, X.; Lupardus, P.; Laporte, S. L.; Garcia, K. C. Structural biology of shared cytokine receptors Annu. Rev. Immunol. 2009, 27, 29-60 10.1146/annurev.immunol.24.021605.090616
22. Casanova, J. L.; Holland, S. M.; Notarangelo, L. D. Inborn errors of human JAKs and STATs Immunity 2012, 36 (4) 515-528 10.1016/j.immuni.2012.03.016
23. Cornejo, M. G.; Boggon, T. J.; Mercher, T. JAK3: a two-faced player in hematological disorders Int. J. Biochem. Cell Biol. 2009, 41 (12) 2376-2379 10.1016/j.biocel.2009.09.004
24. Bains, T.; Heinrich, M. C.; Loriaux, M. M.; Beadling, C.; Nelson, D.; Warrick, A.; Neff, T. L.; Tyner, J. W.; Dunlap, J.; Corless, C. L.; Fan, G. Newly described activating JAK3 mutations in T-cell acute lymphoblastic leukemia Leukemia 2012, 26 (9) 2144-2146 10.1038/leu.2012.74
25. Walters, D. K.; Mercher, T.; Gu, T. L.; O'Hare, T.; Tyner, J. W.; Loriaux, M.; Goss, V. L.; Lee, K. A.; Eide, C. A.; Wong, M. J.; Stoffregen, E. P.; McGreevey, L.; Nardone, J.; Moore, S. A.; Crispino, J.; Boggon, T. J.; Heinrich, M. C.; Deininger, M. W.; Polakiewicz, R. D.; Gilliland, D. G.; Druker, B. J. Activating alleles of JAK3 in acute megakaryoblastic leukemia Cancer Cell 2006, 10 (1) 65-75 10.1016/j.ccr.2006.06.002
26. Koo, G. C.; Tan, S. Y.; Tang, T.; Poon, S. L.; Allen, G. E.; Tan, L.; Chong, S. C.; Ong, W. S.; Tay, K.; Tao, M.; Quek, R.; Loong, S.; Yeoh, K. W.; Yap, S. P.; Lee, K. A.; Lim, L. C.; Tan, D.; Goh, C.; Cutcutache, I.; Yu, W.; Ng, C. C.; Rajasegaran, V.; Heng, H. L.; Gan, A.; Ong, C. K.; Rozen, S.; Tan, P.; Teh, B. T.; Lim, S. T. Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma Cancer Discovery 2012, 2 (7) 591-597 10.1158/2159-8290.CD-12-0028
27. Van Allen, E. M.; Golay, H. G.; Liu, Y.; Koyama, S.; Wong, K.; Taylor-Weiner, A.; Giannakis, M.; Harden, M.; Rojas-Rudilla, V.; Chevalier, A.; Thai, T.; Lydon, C.; Mach, S.; Avila, A. G.; Wong, J. A.; Rabin, A. R.; Helmkamp, J.; Sholl, L.; Carter, S. L.; Oxnard, G.; Janne, P.; Getz, G.; Lindeman, N.; Hammerman, P. S.; Garraway, L. A.; Hodi, F. S.; Rodig, S. J.; Dranoff, G.; Wong, K. K.; Barbie, D. A. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation Cancer Immunol. Res. 2015, 3, 855-863 10.1158/2326-6066.CIR-15-0024
28. Narla, R. K.; Liu, X. P.; Myers, D. E.; Uckun, F. M. 4-(3′-Bromo-4′hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells Clinical Cancer Res. 1998, 4 (6) 1405-1414
29. Chen, J. J.; Thakur, K. D.; Clark, M. P.; Laughlin, S. K.; George, K. M.; Bookland, R. G.; Davis, J. R.; Cabrera, E. J.; Easwaran, V.; De, B.; George Zhang, Y. Development of pyrimidine-based inhibitors of Janus tyrosine kinase 3 Bioorg. Med. Chem. Lett. 2006, 16 (21) 5633-5638 10.1016/j.bmcl.2006.08.022
30. Soth, M.; Hermann, J. C.; Yee, C.; Alam, M.; Barnett, J. W.; Berry, P.; Browner, M. F.; Frank, K.; Frauchiger, S.; Harris, S.; He, Y.; Hekmat-Nejad, M.; Hendricks, T.; Henningsen, R.; Hilgenkamp, R.; Ho, H.; Hoffman, A.; Hsu, P. Y.; Hu, D. Q.; Itano, A.; Jaime-Figueroa, S.; Jahangir, A.; Jin, S.; Kuglstatter, A.; Kutach, A. K.; Liao, C.; Lynch, S.; Menke, J.; Niu, L.; Patel, V.; Railkar, A.; Roy, D.; Shao, A.; Shaw, D.; Steiner, S.; Sun, Y.; Tan, S. L.; Wang, S.; Vu, M. D. 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models J. Med. Chem. 2013, 56 (1) 345-356 10.1021/jm301646k
31. de Vicente, J.; Lemoine, R.; Bartlett, M.; Hermann, J. C.; Hekmat-Nejad, M.; Henningsen, R.; Jin, S.; Kuglstatter, A.; Li, H.; Lovey, A. J.; Menke, J.; Niu, L.; Patel, V.; Petersen, A.; Setti, L.; Shao, A.; Tivitmahaisoon, P.; Vu, M. D.; Soth, M. Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines Bioorg. Med. Chem. Lett. 2014, 24 (21) 4969-4975 10.1016/j.bmcl.2014.09.031
32. Gehringer, M.; Pfaffenrot, E.; Bauer, S.; Laufer, S. A. Design and synthesis of tricyclic JAK3 inhibitors with picomolar affinities as novel molecular probes ChemMedChem 2014, 9 (2) 277-281 10.1002/cmdc.201300520
33. Jaime-Figueroa, S.; De Vicente, J.; Hermann, J.; Jahangir, A.; Jin, S.; Kuglstatter, A.; Lynch, S. M.; Menke, J.; Niu, L.; Patel, V.; Shao, A.; Soth, M.; Vu, M. D.; Yee, C. Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors Bioorg. Med. Chem. Lett. 2013, 23 (9) 2522-2526 10.1016/j.bmcl.2013.03.015
34. Thoma, G.; Nuninger, F.; Falchetto, R.; Hermes, E.; Tavares, G. A.; Vangrevelinghe, E.; Zerwes, H. G. Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family J. Med. Chem. 2011, 54 (1) 284-288 10.1021/jm101157q
35. McDonnell, M. E.; Bian, H.; Wrobel, J.; Smith, G. R.; Liang, S.; Ma, H.; Reitz, A. B. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors Bioorg. Med. Chem. Lett. 2014, 24 (4) 1116-1121 10.1016/j.bmcl.2014.01.001
36. Ross, J. A.; Spadaro, M.; Rosado, D. C.; Cavallo, F.; Kirken, R. A.; Pericle, F. Inhibition of JAK3 with a novel, selective and orally active small molecule induces therapeutic response in T-cell malignancies Leukemia 2014, 28 (4) 941-944 10.1038/leu.2013.309
37. Changelian, P. S.; Flanagan, M. E.; Ball, D. J.; Kent, C. R.; Magnuson, K. S.; Martin, W. H.; Rizzuti, B. J.; Sawyer, P. S.; Perry, B. D.; Brissette, W. H.; McCurdy, S. P.; Kudlacz, E. M.; Conklyn, M. J.; Elliott, E. A.; Koslov, E. R.; Fisher, M. B.; Strelevitz, T. J.; Yoon, K.; Whipple, D. A.; Sun, J.; Munchhof, M. J.; Doty, J. L.; Casavant, J. M.; Blumenkopf, T. A.; Hines, M.; Brown, M. F.; Lillie, B. M.; Subramanyam, C.; Shang-Poa, C.; Milici, A. J.; Beckius, G. E.; Moyer, J. D.; Su, C.; Woodworth, T. G.; Gaweco, A. S.; Beals, C. R.; Littman, B. H.; Fisher, D. A.; Smith, J. F.; Zagouras, P.; Magna, H. A.; Saltarelli, M. J.; Johnson, K. S.; Nelms, L. F.; Des Etages, S. G.; Hayes, L. S.; Kawabata, T. T.; Finco-Kent, D.; Baker, D. L.; Larson, M.; Si, M. S.; Paniagua, R.; Higgins, J.; Holm, B.; Reitz, B.; Zhou, Y. J.; Morris, R. E.; O'Shea, J. J.; Borie, D. C. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor Science 2003, 302 (5646) 875-878 10.1126/science.1087061
38. Pattison, M. J.; Mackenzie, K. F.; Arthur, J. S. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback J. Immunol. 2012, 189 (6) 2784-2792 10.4049/jimmunol.1200310
39. Liao, W.; Spolski, R.; Li, P.; Du, N.; West, E. E.; Ren, M.; Mitra, S.; Leonard, W. J. Opposing actions of IL-2 and IL-21 on Th9 differentiation correlate with their differential regulation of BCL6 expression Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (9) 3508-3513 10.1073/pnas.1301138111
40. Bouchekioua, A.; Scourzic, L.; de Wever, O.; Zhang, Y.; Cervera, P.; Aline-Fardin, A.; Mercher, T.; Gaulard, P.; Nyga, R.; Jeziorowska, D.; Douay, L.; Vainchenker, W.; Louache, F.; Gespach, C.; Solary, E.; Coppo, P. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma Leukemia 2014, 28 (2) 338-348 10.1038/leu.2013.157
41. Liu, Q.; Sabnis, Y.; Zhao, Z.; Zhang, T.; Buhrlage, S. J.; Jones, L. H.; Gray, N. S. Developing irreversible inhibitors of the protein kinase cysteinome Chem. Biol. 2013, 20 (2) 146-159 10.1016/j.chembiol.2012.12.006
42. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 2008, 27 (34) 4702-4711 10.1038/onc.2008.109
43. Brown, J. R. Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials Current hematologic malignancy reports 2013, 8 (1) 1-6 10.1007/s11899-012-0147-9
44. Zhou, W.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Janne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462 (7276) 1070-1074 10.1038/nature08622
45. Flanagan, M. E.; Abramite, J. A.; Anderson, D. P.; Aulabaugh, A.; Dahal, U. P.; Gilbert, A. M.; Li, C.; Montgomery, J.; Oppenheimer, S. R.; Ryder, T.; Schuff, B. P.; Uccello, D. P.; Walker, G. S.; Wu, Y.; Brown, M. F.; Chen, J. M.; Hayward, M. M.; Noe, M. C.; Obach, R. S.; Philippe, L.; Shanmugasundaram, V.; Shapiro, M. J.; Starr, J.; Stroh, J.; Che, Y. Chemical and computational methods for the characterization of covalent reactive groups for the prospective design of irreversible inhibitors J. Med. Chem. 2014, 57 (23) 10072-10079 10.1021/jm501412a
46. Zambaldo, C.; Sadhu, K. K.; Karthikeyan, G.; Barluenga, S.; Daguer, J.-P.; Winssinger, N. Selective affinity-based probe for oncogenic kinases suitable for live cell imaging Chemical Science 2013, 4 (5) 2088-2092 10.1039/c3sc21856b
47. London, N.; Miller, R. M.; Krishnan, S.; Uchida, K.; Irwin, J. J.; Eidam, O.; Gibold, L.; Cimermancic, P.; Bonnet, R.; Shoichet, B. K.; Taunton, J. Covalent docking of large libraries for the discovery of chemical probes Nat. Chem. Biol. 2014, 10 (12) 1066-1072 10.1038/nchembio.1666
48. Goedken, E. R.; Argiriadi, M. A.; Banach, D. L.; Fiamengo, B. A.; Foley, S. E.; Frank, K. E.; George, J. S.; Harris, C. M.; Hobson, A. D.; Ihle, D. C.; Marcotte, D.; Merta, P. J.; Michalak, M. E.; Murdock, S. E.; Tomlinson, M. J.; Voss, J. W. Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol J. Biol. Chem. 2015, 290 (8) 4573-4589 10.1074/jbc.M114.595181
49. Lacronique, V.; Boureux, A.; Monni, R.; Dumon, S.; Mauchauffe, M.; Mayeux, P.; Gouilleux, F.; Berger, R.; Gisselbrecht, S.; Ghysdael, J.; Bernard, O. A. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells Blood 2000, 95 (6) 2076-2083
50. Goldstein, D. M.; Gray, N. S.; Zarrinkar, P. P. High-throughput kinase profiling as a platform for drug discovery Nat. Rev. Drug Discovery 2008, 7 (5) 391-397 10.1038/nrd2541
51. Miduturu, C. V.; Deng, X.; Kwiatkowski, N.; Yang, W.; Brault, L.; Filippakopoulos, P.; Chung, E.; Yang, Q.; Schwaller, J.; Knapp, S.; King, R. W.; Lee, J. D.; Herrgard, S.; Zarrinkar, P.; Gray, N. S. High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors Chem. Biol. 2011, 18 (7) 868-879 10.1016/j.chembiol.2011.05.010
52. Lebakken, C. S.; Riddle, S. M.; Singh, U.; Frazee, W. J.; Eliason, H. C.; Gao, Y.; Reichling, L. J.; Marks, B. D.; Vogel, K. W. Development and applications of a broad-coverage, TR-FRET-based kinase binding assay platform J. Biomol. Screening 2009, 14 (8) 924-935 10.1177/1087057109339207
53. Warmuth, M.; Kim, S.; Gu, X. J.; Xia, G.; Adrian, F. Ba/F3 cells and their use in kinase drug discovery Curr. Opin. Oncol. 2007, 19 (1) 55-60 10.1097/CCO.0b013e328011a25f
54. Sanda, T.; Tyner, J. W.; Gutierrez, A.; Ngo, V. N.; Glover, J.; Chang, B. H.; Yost, A.; Ma, W.; Fleischman, A. G.; Zhou, W.; Yang, Y.; Kleppe, M.; Ahn, Y.; Tatarek, J.; Kelliher, M. A.; Neuberg, D. S.; Levine, R. L.; Moriggl, R.; Muller, M.; Gray, N. S.; Jamieson, C. H.; Weng, A. P.; Staudt, L. M.; Druker, B. J.; Look, A. T. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia Cancer Discovery 2013, 3 (5) 564-577 10.1158/2159-8290.CD-12-0504
55. Fleischmann, R. M.; Damjanov, N. S.; Kivitz, A. J.; Legedza, A.; Hoock, T.; Kinnman, N. A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis Arthritis Rheumatol. 2015, 67 (2) 334-343 10.1002/art.38949
56. Pardanani, A.; Lasho, T.; Smith, G.; Burns, C. J.; Fantino, E.; Tefferi, A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients Leukemia 2009, 23 (8) 1441-1445 10.1038/leu.2009.50
57. Kwiatkowski, N.; Jelluma, N.; Filippakopoulos, P.; Soundararajan, M.; Manak, M. S.; Kwon, M.; Choi, H. G.; Sim, T.; Deveraux, Q. L.; Rottmann, S.; Pellman, D.; Shah, J. V.; Kops, G. J.; Knapp, S.; Gray, N. S. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function Nat. Chem. Biol. 2010, 6 (5) 359-368 10.1038/nchembio.345
58. Li, X.; He, Y.; Ruiz, C. H.; Koenig, M.; Cameron, M. D. Characterization of dasatinib and its structural analogs as CYP3A4 mechanism-based inactivators and the proposed bioactivation pathways Drug Metab. Dispos. 2009, 37 (6) 1242-1250 10.1124/dmd.108.025932
59. Cross, D. A.; Ashton, S. E.; Ghiorghiu, S.; Eberlein, C.; Nebhan, C. A.; Spitzler, P. J.; Orme, J. P.; Finlay, M. R.; Ward, R. A.; Mellor, M. J.; Hughes, G.; Rahi, A.; Jacobs, V. N.; Brewer, M. R.; Ichihara, E.; Sun, J.; Jin, H.; Ballard, P.; Al-Kadhimi, K.; Rowlinson, R.; Klinowska, T.; Richmond, G. H.; Cantarini, M.; Kim, D. W.; Ranson, M. R.; Pao, W. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discovery 2014, 4 (9) 1046-1061 10.1158/2159-8290.CD-14-0337
60. Cortes, J. R.; Perez-G, M.; Rivas, M. D.; Zamorano, J. Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3 J. Immunol. 2007, 179 (6) 3881-3887 10.4049/jimmunol.179.6.3881
61. O'Sullivan, L. A.; Liongue, C.; Lewis, R. S.; Stephenson, S. E. M.; Ward, A. C. Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease Mol. Immunol. 2007, 44 (10) 2497-2506 10.1016/j.molimm.2006.11.025
62. Ji, H.; Ramsey, M. R.; Hayes, D. N.; Fan, C.; McNamara, K.; Kozlowski, P.; Torrice, C.; Wu, M. C.; Shimamura, T.; Perera, S. A.; Liang, M. C.; Cai, D.; Naumov, G. N.; Bao, L.; Contreras, C. M.; Li, D.; Chen, L.; Krishnamurthy, J.; Koivunen, J.; Chirieac, L. R.; Padera, R. F.; Bronson, R. T.; Lindeman, N. I.; Christiani, D. C.; Lin, X.; Shapiro, G. I.; Janne, P. A.; Johnson, B. E.; Meyerson, M.; Kwiatkowski, D. J.; Castrillon, D. H.; Bardeesy, N.; Sharpless, N. E.; Wong, K. K. LKB1 modulates lung cancer differentiation and metastasis Nature 2007, 448 (7155) 807-810 10.1038/nature06030
63. Herter-Sprie, G. S.; Korideck, H.; Christensen, C. L.; Herter, J. M.; Rhee, K.; Berbeco, R. I.; Bennett, D. G.; Akbay, E. A.; Kozono, D.; Mak, R. H.; Mike Makrigiorgos, G.; Kimmelman, A. C.; Wong, K. K. Image-guided radiotherapy platform using single nodule conditional lung cancer mouse models Nat. Commun. 2014, 5, 5870 10.1038/ncomms6870
64. Eling, T. E.; DiAugustine, R. P. A role for phospholipids in the binding and metabolism of drugs by hepatic microsomes. Use of the fluorescent hydrophobic probe 1-anilinonaphthalene-8-sulphonate Biochem. J. 1971, 123 (4) 539-549 10.1042/bj1230539
65. Z′-Lyte assays, http://www.lifetechnologies.com/content/dam/LifeTech/migration/files/drug-discovery/pdfs.par.60256.file.dat/20130430%20ssbk%20customer%20protocol%20and%20assay%20conditions.pdf; TTK assay, http://tools.lifetechnologies.com/content/sfs/manuals/TTK-LanthaScreen-Binding.pdf; Invitrogen Corporation: Madison, WI.
66. Boggon, T. J.; Li, Y.; Manley, P. W.; Eck, M. J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog Blood 2005, 106 (3) 996-1002 10.1182/blood-2005-02-0707
67. Kabsch, W. XDS Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66 (2) 125-132 10.1107/S0907444909047337
68. Evans, P. Scaling and assessment of data quality Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62 (1) 72-82 10.1107/S0907444905036693
69. Winn, M. D.; Ballard, C. C.; Cowtan, K. D.; Dodson, E. J.; Emsley, P.; Evans, P. R.; Keegan, R. M.; Krissinel, E. B.; Leslie, A. G.; McCoy, A.; McNicholas, S. J.; Murshudov, G. N.; Pannu, N. S.; Potterton, E. A.; Powell, H. R.; Read, R. J.; Vagin, A.; Wilson, K. S. Overview of the CCP4 suite and current developments Acta Crystallogr., Sect. D: Biol. Crystallogr. 2011, 67 (4) 235-242 10.1107/S0907444910045749
70. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software J. Appl. Crystallogr. 2007, 40 (4) 658-674 10.1107/S0021889807021206
71. Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66 (4) 486-501 10.1107/S0907444910007493
72. Adams, P. D.; Afonine, P. V.; Bunkoczi, G.; Chen, V. B.; Davis, I. W.; Echols, N.; Headd, J. J.; Hung, L. W.; Kapral, G. J.; Grosse-Kunstleve, R. W.; McCoy, A. J.; Moriarty, N. W.; Oeffner, R.; Read, R. J.; Richardson, D. C.; Richardson, J. S.; Terwilliger, T. C.; Zwart, P. H. PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66 (2) 213-221 10.1107/S0907444909052925
73. Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O. BUSTER, version 2.10.2; Global Phasing Ltd.: Cambridge, United Kingdom, 2011.
74. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60 (8) 1355-1363 10.1107/S0907444904011679
75. Zhang, T.; Inesta-Vaquera, F.; Niepel, M.; Zhang, J.; Ficarro, S. B.; Machleidt, T.; Xie, T.; Marto, J. A.; Kim, N.; Sim, T.; Laughlin, J. D.; Park, H.; LoGrasso, P. V.; Patricelli, M.; Nomanbhoy, T. K.; Sorger, P. K.; Alessi, D. R.; Gray, N. S. Discovery of potent and selective covalent inhibitors of JNK Chem. Biol. 2012, 19 (1) 140-154 10.1016/j.chembiol.2011.11.010
76. Zhang, Z.; Marshall, A. G. A universal algorithm for fast and automated charge state deconvolution of electrospray mass-to-charge ratio spectra J. Am. Soc. Mass Spectrom. 1998, 9 (3) 225-233 10.1016/S1044-0305(97)00284-5
77. Ficarro, S. B.; Zhang, Y.; Lu, Y.; Moghimi, A. R.; Askenazi, M.; Hyatt, E.; Smith, E. D.; Boyer, L.; Schlaeger, T. M.; Luckey, C. J.; Marto, J. A. Improved electrospray ionization efficiency compensates for diminished chromatographic resolution and enables proteomics analysis of tyrosine signaling in embryonic stem cells Anal. Chem. 2009, 81 (9) 3440-3447 10.1021/ac802720e
78. Askenazi, M.; Parikh, J. R.; Marto, J. A. mzAPI: a new strategy for efficiently sharing mass spectrometry data Nat. Methods 2009, 6 (4) 240-241 10.1038/nmeth0409-240
79. McGuire, V. A.; Gray, A.; Monk, C. E.; Santos, S. G.; Lee, K.; Aubareda, A.; Crowe, J.; Ronkina, N.; Schwermann, J.; Batty, I. H.; Leslie, N. R.; Dean, J. L.; O'Keefe, S. J.; Boothby, M.; Gaestel, M.; Arthur, J. S. Cross talk between the Akt and p38alpha pathways in macrophages downstream of Toll-like receptor signaling Mol. Cell. Biol. 2013, 33 (21) 4152-4165 10.1128/MCB.01691-12
80. Akbay, E. A.; Koyama, S.; Carretero, J.; Altabef, A.; Tchaicha, J. H.; Christensen, C. L.; Mikse, O. R.; Cherniack, A. D.; Beauchamp, E. M.; Pugh, T. J.; Wilkerson, M. D.; Fecci, P. E.; Butaney, M.; Reibel, J. B.; Soucheray, M.; Cohoon, T. J.; Janne, P. A.; Meyerson, M.; Hayes, D. N.; Shapiro, G. I.; Shimamura, T.; Sholl, L. M.; Rodig, S. J.; Freeman, G. J.; Hammerman, P. S.; Dranoff, G.; Wong, K. K. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors Cancer Discovery 2013, 3 (12) 1355-1363 10.1158/2159-8290.CD-13-0310